Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 2 of 53 for:    diabetes periodontitis

Propolis Improves Glycemic Control in Subjects With Type 2 Diabetes and Chronic Periodontitis

This study has been completed.
Mansoura University
Information provided by (Responsible Party):
Mohamed Anees, Mansoura University Identifier:
First received: May 29, 2016
Last updated: June 8, 2016
Last verified: May 2016


Propolis is a natural resin made by bees from various plant sources. Propolis exerts antimicrobial, anti-inflammatory, immunomodulatory, antioxidant, and antidiabetic properties. The purpose of this study was to assess the adjunctive benefit of propolis supplementation in individuals with both chronic periodontitis and type 2 diabetes mellitus (T2DM) receiving scaling and root planing (SRP).


A 6-month randomized blinded clinical trial comparing SRP with placebo (placebo+SRP group, n=26) or combined with a 6- month regimen of 400 mg oral propolis once daily (propolis+SRP group, n=26) was performed in patients with long-standing T2DM and chronic periodontitis. Treatment outcomes included hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), serum N€-(carboxymethyl) lysine (CML) and changes in periodontal parameters.

Condition Intervention Phase
Diabetes Mellitus
Drug: Propolis
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Propolis Improves Periodontal Status and Glycemic Control in Subjects With Type 2 Diabetes Mellitus and Chronic Periodontitis: a Randomized Clinical Trial

Further study details as provided by Mansoura University:

Primary Outcome Measures:
  • Change of glycosylated hemoglobin (HbA1c) [ Time Frame: Baseline, 3 and 6 months ]
    HbA1c was evaluated at baseline,3 and 6 months

Secondary Outcome Measures:
  • Change of pocket depth [ Time Frame: From baseline and 6 months ]
  • Change of clinical attachment level [ Time Frame: From baseline and 6 months ]
  • Change of fasting plasma glucose level [ Time Frame: From baseline and 6 months ]
  • Change of serum N- epsilon (carboxymethyl) lysine level [ Time Frame: From baseline and 6 months ]

Enrollment: 52
Study Start Date: June 2014
Study Completion Date: March 2015
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Propolis
400 mg oral proplois (capsule) was given to participants once daily for 6 months after performing scaling and root planing.
Drug: Propolis
Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
Other Name: BioPropolis
Placebo Comparator: Placebo
Placebo capsule was given to participants once daily for 6 months after performing scaling and root planing.
Drug: Placebo
Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
Other Name: Starch capsules

  Show Detailed Description


Ages Eligible for Study:   38 Years to 63 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients had type 2 diabetes mellitus with a minimum of five years duration and had been taking stable doses of oral hypoglycemic drugs and/or insulin for at least 6 months.
  • Patients should have chronic periodontitis with probing pocket depth and clinical attachment loss ≥ 5 mm with detectable bleeding on probing in at least one site in each sextant.
  • Patients should have a minimum of 20 teeth to be selected.
  • All patients were diagnosed to have moderate to severe chronic periodontitis according to Armitage criteria.

Exclusion Criteria:

  • Smokers.
  • Recent extended use of antibiotics or non-steroidal anti-inflammatory drugs within the last 3 months.
  • Patients who had any periodontal therapy within one year.
  • Patients with grade 3 or 4 retinopathy.
  • Pregnancy.
  • Women using oral contraceptives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02794506

Faculty of Dentistry
Mansoura, Dakahlia, Egypt
Sponsors and Collaborators
Mohamed Anees
Mansoura University
Study Director: Hesham M. El-Sharkawy, Ass.Prof. Mansoura University
  More Information


Responsible Party: Mohamed Anees, Lecturer of Oral Medicine and Periodontology, Mansoura University Identifier: NCT02794506     History of Changes
Other Study ID Numbers: DENT-1971
Study First Received: May 29, 2016
Last Updated: June 8, 2016
Individual Participant Data  
Plan to Share IPD: Yes

Keywords provided by Mansoura University:
Diabetes mellitus
Chronic periodontitis

Additional relevant MeSH terms:
Diabetes Mellitus
Chronic Periodontitis
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Anti-Infective Agents processed this record on April 25, 2017